免疫比濁法試劑市場 - 全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

全球免疫比濁試劑市場預計將從 2025 年的 55.3 億美元成長到 2031 年的 79.3 億美元，複合年成長率為 6.19%。

這些試劑是重要的診斷產品，透過測量抗原-抗體反應產生的濁度來定量臨床檢體中的特定蛋白質濃度。推動這一成長的主要動力是全球慢性疾病負擔日益加重，需要頻繁監測C反應蛋白和糖化血紅蛋白（HbA1c）等生物標記。因此，病理檢查室對精確的蛋白質測量工具的需求持續強勁。根據國際糖尿病聯盟的數據，到2024年，全球約有5.89億成年人將患有糖尿病，這項數據凸顯了長期診斷監測日益成長的需求。

儘管市場需求強勁，但由於體外診斷領域嚴格的法規結構，市場仍面臨許多障礙。製造商必須應對複雜的合規要求和漫長的新試劑配方核准流程，這往往會導致營運成本增加和市場准入延遲。在實施新的醫療設備法規的地區，這些監管壓力尤其突出，對中小企業構成重大挑戰。最終，這種環境可能會限制價格敏感型新興市場中經濟實惠的檢測解決方案的供應。

市場促進因素

全球老年人口的成長以及隨之而來的合併症增多是免疫比濁試劑市場的主要促進因素。隨著老齡化，全身性發炎和器官功能障礙的風險增加，因此需要定期定量檢測特定血漿蛋白，例如免疫球蛋白、微量白蛋白和C反應蛋白。由於老年人通常需要持續管理多種慢性疾病，因此這一人口趨勢顯著增加了老年醫學所需的診斷檢測量。世界衛生組織（WHO）於2025年2月發布的數據顯示，2024年全球平均壽命將達到73.3歲，凸顯了需要醫療監測的時間延長。這一趨勢在人口快速老化的地區尤其明顯；根據《中國日報》2025年12月報道，到2024年底，中國60歲及以上人口將達到3.1億，這將形成一個巨大的蛋白質檢測市場。

自動化、高通量診斷平台的普及進一步加速了市場成長，這些平台提高了檢查室的處理能力和效率。現代病理檢查室擴大採用模組化系統，利用先進的免疫比濁法快速處理大量檢體，最大限度地減少人工干預。這種向自動化的轉變需要高度穩定的試劑來確保自動化生產線的準確性，從而確保製造商的持續收入。這種營運模式的變革所帶來的財務影響顯而易見。羅氏於2025年1月發布的「2024會計年度業績」顯示，其診斷部門的核心業務收入成長了8%。這主要得益於市場對免疫診斷解決方案的強勁成長動能和需求。

市場挑戰

嚴格的法規結構對全球免疫比濁試劑市場的成長構成重大阻礙。製造商面臨著應對複雜合規通訊協定的挑戰，包括體外診斷藥物法規的修訂，這些修訂要求進行嚴格的穩定性檢驗並提供大量的臨床證據。這種嚴格的監管體系延長了產品核可週期，迫使企業將大量資金投入維持認證而非研發。因此，這些高進入門檻阻礙了中小企業進入市場，迫使現有企業精簡產品系列，並常常導致一些在新成本結構下不再具有商業性可行性的小眾試劑停產。

監管壓力帶來的負面影響在企業策略決策中顯而易見，這些企業傾向於避免在監管要求最嚴格的地區推出產品。根據《2024年歐洲醫療技術展報告》，領先的製造商已將歐盟作為新型體外診斷設備主要上市地區的偏好降低了40%，理由是歐盟監管環境資源密集且難以預測。這一趨勢將減緩全球先進免疫比濁法的檢測法，限制病理檢查室及時獲得診斷工具，並最終阻礙整體市場收入成長。

市場趨勢

隨著乳膠增強免疫比濁法的日益普及，市場模式正在重塑。該技術克服了傳統檢測方法的靈敏度限制。實驗室正轉向使用這些先進的基於顆粒的配方，無需專用比濁儀，即可使用標準生化分析儀對D-二聚體和Cystatin C等低豐度蛋白進行精確定量。這項技術進步實現了工作流程的整合，並顯著降低了每次檢測的成本，從而推動了核心病理中心對高性能試劑的需求。近期產業業績也印證了這項營運優勢。 2025年1月，雅培在其「2024會計年度第四季及全年業績」報告中指出，不計新冠肺炎相關收入，其全球診斷銷售額成長了4.3%，這反映出人們對常規核心檢查室檢測的依賴性日益增強。

試劑供應的關鍵發展在於與照護現場和微流體平台的整合，這需要將化學品重新配製成穩定的微量形式，以便進行分散式檢查。製造商正積極採用免疫比濁試劑，用於基於卡盒的系統，即使在偏遠地區和缺乏濕化學分析儀的急救醫療機構，也能實現快速蛋白質分析。診斷可近性的擴大正在推動全球檢測量的成長。根據羅氏於2025年2月發布的2024會計年度年度報告，2024年全球診斷產業共進行了300億次檢測。這項檢測量的成長得益於各項策略性舉措，這些舉措將診斷能力從中心檢查室擴展到以病人為中心的醫療機構。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：免疫比濁法試劑的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 類型（普通免疫比濁試劑、乳膠增強型免疫比濁試劑）
  • 透過應用（醣化血紅素、視網醇結合蛋白質、C反應蛋白、抗鏈球菌溶血素O、類風濕因子等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美免疫比濁法試劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲免疫比濁試劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區免疫比濁試劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲免疫比濁試劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲免疫比濁試劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球免疫比濁試劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Immunoturbidimetry Reagents Market is projected to expand from a valuation of USD 5.53 Billion in 2025 to USD 7.93 Billion by 2031, reflecting a CAGR of 6.19%. These reagents are essential diagnostic formulations designed to quantify specific protein levels in clinical samples by measuring the turbidity generated from antigen-antibody interactions. A major factor driving this growth is the increasing global burden of chronic diseases, which demands frequent monitoring of biological markers like C-reactive protein and HbA1c. Consequently, pathology laboratories are experiencing a sustained need for accurate protein estimation tools. Data from the International Diabetes Federation indicates that approximately 589 million adults worldwide were living with diabetes in 2024, a statistic that underscores the growing necessity for long-term diagnostic monitoring.

Despite robust demand, the market faces significant hurdles due to the strict regulatory frameworks governing in vitro diagnostics. Manufacturers must navigate intricate compliance mandates and prolonged approval timelines for new reagent formulations, which often result in higher operational costs and delayed market entry. These regulatory pressures are especially intense in regions enforcing new medical device regulations, creating substantial barriers for smaller companies. Ultimately, this environment risks restricting the availability of affordable testing solutions in price-sensitive emerging markets.

Market Driver

The expanding global geriatric population and the rise of associated comorbidities serve as primary catalysts for the immunoturbidimetry reagents market. As individuals age, they become more susceptible to systemic inflammation and organ dysfunction, necessitating regular quantification of specific plasma proteins like immunoglobulins, microalbumin, and C-reactive protein. This demographic trend significantly increases the volume of diagnostic tests required for geriatric care, as older adults frequently need ongoing management for multiple chronic conditions. According to the World Health Organization in February 2025, global life expectancy reached 73.3 years in 2024, emphasizing the extended duration requiring medical monitoring. This is particularly pronounced in rapidly aging regions; China Daily reported in December 2025 that China's population aged 60 and older hit 310 million by the end of 2024, representing a vast market for protein estimation assays.

Market growth is further accelerated by the widespread adoption of automated high-throughput diagnostic platforms, which improve laboratory capacity and efficiency. Modern pathology labs are increasingly adopting modular systems that utilize advanced immunoturbidimetric assays to process large sample volumes rapidly with minimal manual input. This shift towards automation requires high-stability reagents that ensure precision on automated lines, thereby guaranteeing recurring revenue for manufacturers. The financial impact of this operational evolution is clear; Roche's '2024 Annual Results' released in January 2025 noted an 8% increase in the Diagnostics Division's base business sales, driven largely by the strong momentum and demand for immunodiagnostic solutions.

Market Challenge

Strict regulatory frameworks impose a major obstacle to the growth of the Global Immunoturbidimetry Reagents Market. Manufacturers face the challenge of navigating intricate compliance protocols, including updated in vitro diagnostic regulations that necessitate rigorous stability validation and extensive clinical evidence. This intense scrutiny extends the product approval lifecycle and forces companies to direct heavy capital towards maintaining certifications rather than research and development. Consequently, these high entry barriers deter smaller enterprises from competing and compel established companies to streamline their portfolios, frequently resulting in the discontinuation of niche reagents that become commercially unviable under the new cost structures.

The detrimental impact of regulatory pressure is evident in the strategic decision to divert product launches away from regions with the most demanding mandates. According to MedTech Europe in 2024, large manufacturers reduced their prioritization of the European Union as a primary launch geography for new in vitro diagnostic devices by 40%, citing the resource intensity and unpredictability of the regulatory landscape. This trend postpones the global availability of advanced immunoturbidimetry assays, limiting pathology laboratories' access to timely diagnostic tools and ultimately retarding the market's overall revenue growth.

Market Trends

The market is being reshaped by the increasing adoption of latex-enhanced immunoturbidimetry, which resolves the sensitivity limitations of traditional assays. Laboratories are shifting toward these advanced particle-based formulations to accurately quantify low-abundance proteins, such as D-dimer and Cystatin C, on standard biochemistry analyzers without the need for specialized nephelometric equipment. This technological advancement allows for workflow consolidation and a significant reduction in cost-per-test, fueling demand for high-performance reagents in core pathology centers. This operational strength is highlighted by recent industry performance; in January 2025, Abbott reported in its 'Fourth-Quarter and Full-Year 2024 Results' that global Diagnostics sales, excluding COVID-19 revenue, rose by 4.3%, reflecting the growing reliance on routine core laboratory testing.

A critical evolution in reagent delivery is the integration with point-of-care and microfluidic platforms, requiring the reformulation of chemistries into stable, micro-volume formats for decentralized testing. Manufacturers are actively adapting immunoturbidimetric reagents for use in cartridge-based systems, enabling rapid protein profiling in remote settings and urgent care facilities where wet chemistry analyzers are not feasible. This expansion of diagnostic access is driving global testing volumes higher; according to Roche's 'Annual Report 2024' published in February 2025, the Diagnostics division delivered 30 billion tests globally in 2024, a volume supported by the strategic initiative to extend diagnostic capabilities from central labs to near-patient environments.

Key Market Players

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

Report Scope

In this report, the Global Immunoturbidimetry Reagents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoturbidimetry Reagents Market, By Type

• Common Immune Turbidimetric Reagent
• Latex Enhanced Immune Turbidimetric Reagent

Immunoturbidimetry Reagents Market, By Application

• Glycated hemoglobin
• Retinol Binding Protein
• C-Reactive Protein
• Anti-streptococcal hemolysin "O"
• Rheumatoid Factor
• Other

Immunoturbidimetry Reagents Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoturbidimetry Reagents Market.

Available Customizations:

Global Immunoturbidimetry Reagents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoturbidimetry Reagents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Common Immune Turbidimetric Reagent, Latex Enhanced Immune Turbidimetric Reagent)
  • 5.2.2. By Application (Glycated hemoglobin, Retinol Binding Protein, C-Reactive Protein, Anti-streptococcal hemolysin "O", Rheumatoid Factor, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Immunoturbidimetry Reagents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoturbidimetry Reagents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Immunoturbidimetry Reagents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Immunoturbidimetry Reagents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Immunoturbidimetry Reagents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoturbidimetry Reagents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Immunoturbidimetry Reagents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Immunoturbidimetry Reagents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Immunoturbidimetry Reagents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Immunoturbidimetry Reagents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Immunoturbidimetry Reagents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunoturbidimetry Reagents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Immunoturbidimetry Reagents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Immunoturbidimetry Reagents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Immunoturbidimetry Reagents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Immunoturbidimetry Reagents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Immunoturbidimetry Reagents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunoturbidimetry Reagents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Immunoturbidimetry Reagents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Immunoturbidimetry Reagents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Immunoturbidimetry Reagents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunoturbidimetry Reagents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Immunoturbidimetry Reagents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Immunoturbidimetry Reagents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunoturbidimetry Reagents Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc
• 15.3. Siemens Healthineers AG
• 15.4. F. Hoffmann-La Roche AG
• 15.5. DIALAB GmbH
• 15.6. Shanghai Kehua Bio-Engineering Co Ltd
• 15.7. Randox Laboratories Ltd
• 15.8. Beijing Leadman Biochemistry Co Ltd
• 15.9. Fujifilm Corp
• 15.10. Mindray Medical International Ltd

16. Strategic Recommendations

17. About Us & Disclaimer